Jivi

Damoctocog alfa pegol, the active ingredient in Jivi, is a recombinant factor VIII product presented as a solution for injection for intravenous use. It replaces the deficient clotting factor in patients with hemophilia A, helping to control and prevent bleeding episodes.

GNH USA supplies Jivi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jivi is a recombinant factor VIII therapy used within the hemophilia A treatment pathway.

Prophylaxis: reduces the frequency of spontaneous bleeding episodes in patients with hemophilia A. Acute Bleeding Treatment: controls and stops active bleeding episodes in hemophilia A patients. Surgical Coverage: provides hemostatic support during surgical procedures for individuals with hemophilia A.

Jivi may be associated with several adverse reactions.

Common Side Effects: - Injection site pain or erythema - Headache - Fever or chills - Arthralgia - Nausea - Fatigue

Serious or Rare Side Effects: - Development of inhibitory antibodies against factor VIII - Anaphylactic or severe hypersensitivity reactions - Thromboembolic events - Severe hemolysis - Disseminated intravascular coagulation (DIC)

When using Jivi, certain precautions should be observed. - Individualized Dosing: dosing must be determined by a qualified prescriber based on patient-specific factors. - Inhibitor Monitoring: regularly assess for development of factor VIII inhibitors. - Hypersensitivity: avoid in patients with known allergy to the product or its excipients. - Concomitant Anticoagulants: use caution if the patient is receiving other anticoagulant therapies. - Renal/Hepatic Function: evaluate organ function before initiating therapy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Jivi can interact with other medicines, requiring attention to potential effects.

Major Interactions (Avoid): - Concurrent use with other factor VIII concentrates may increase inhibitor risk. - Simultaneous administration with high‑dose anticoagulants can compromise hemostasis.

Moderate Interactions (Monitor Closely): - Certain antibiotics (e.g., aminoglycosides) may interfere with clotting assays. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) may elevate bleeding tendency. - Immunosuppressive agents could affect inhibitor development monitoring.